Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

The Pieces Are Now Falling into Place in Ovarian Cancer Surgery

The Pieces Are Now Falling into Place in Ovarian Cancer Surgery

In advanced ovarian cancer, extensive removal of neighboring lymph nodes in addition to the primary tumor did not improve survival but caused more adverse effects, as shown on 28 February 2019 in NEJM by the published LION clinical trial.

A video summary of the LION study is below:

For advanced ovarian cancers, the main treatment is surgery aiming to remove all visible tumors completely—called macroscopic R0 resection—followed by carboplatin-paclitaxel chemotherapy.

The most important determinant of surgical outcomes in ovarian cancer is how much tumor remains after surgery. If no macroscopically visible tumor remains, it is considered completely removed. Lymphatic vessels are a route of spread common to both early and advanced ovarian cancer and an important factor in predicting disease course. Studies to date have found lymph node metastases during surgery in % 44 - 53 of patients. Some retrospective (backward-looking) data suggest that extensive removal of pelvic and paraaortic nodes around the ovaries improves survival, but no prospective (forward-looking) randomized trial had demonstrated this benefit. The Lymphadenectomy in Ovarian Neoplasms (LION) study was conducted for this purpose.

Study Method

Patients with ovarian cancer from stage IIB through stage 4, normal lymph nodes before and during surgery, and macroscopically complete tumor removal were enrolled, totaling 647 patients. Enrolled between 2008 and 2012, participants were randomized to lymphadenectomy (323 patients) or no lymphadenectomy (324 patients). All participating centers were assessed before the study regarding oncological surgery to ensure that they met quality standards. The study’s primary endpoint was defined as overall survival.

Results of the LION Study

  • Patients undergoing lymphadenectomy had a median of 57 lymph nodes removed (35 pelvic and 22 paraaortic nodes).
  • Comparing median overall survival, patients undergoing lymphadenectomy had 65.5 months, while those without lymph node removal had 69.2 months.
  • Median progression-free survival was 25.5 months in both groups.
  • Serious postoperative adverse effects were significantly more frequent in the lymphadenectomy group (%12.4 versus %6.5).
  • Mortality (death) within the first 60 days after surgery was %3.1 with lymphadenectomy and %0.9 without it.

In conclusion, in patients with advanced ovarian cancer whose tumor was completely removed and whose lymph nodes were normal before and during surgery, systematic pelvic and paraaortic lymphadenectomy improved neither overall nor progression-free survival. It also caused more postoperative adverse effects.

Sources

P. Harter, J. Sehouli, D. Lorusso ve ark.
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.
NEJM, 28 February 2019

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

The Pieces Are Now Falling into Place in Ovarian Cancer Surgery

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy